AboutContact us
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Serbia opens Israeli drone factory as defense ties with Elbit deepen
2
The man who helped build Palo Alto’s Cortex is leaving the company
3
“Our next milestone will be a billion-dollar valuation”: MIND triples valuation to $300 million with $72 million Series B
4
How an Israeli engineer went from Rafael to iPhone Portrait Mode and a $300 million OpenAI exit
5
Sayeret Matkal veterans raise $22 million to teach the world English with AI
More news

Pharmaceuticals

20 stories about Pharmaceuticals
וורן באפט אסיפת בעלי המניות מאי 2018

Berkshire Hathaway Solidified its Teva Position in 2018 First Quarter

16.05.18|Lilach Baumer
According to a Tuesday filing, Berkshire Hathaway more than doubled its Teva stake during the first quarter of 2018
בריאות דיגיטלית מדעי החיים רפואה טיפול 1

Israel’s Life Sciences Industry Is Dominated by Small Scale Startups

14.05.18|Lilach Baumer
65% of all Israel-based life sciences companies employ 10 people or less, according to a new report
מטה טבע פתח תקווה

Building on Strong First Quarter, Teva Raises 2018 Outlook

03.05.18|Lilach Baumer and Dror Reich
The company reported a 10% decrease in revenues compared to 2017, largely due to North American Copaxone troubles, but beat analyst expectations
default image

Pharma Company Opko Health Retracts Decision to Delist From the Tel Aviv Stock Exchange

29.04.18|Racheli Bindman
Dually listed on Nasdaq and TASE, Opko first submitted a request to delist from the TASE in early April
מוסף 16.5 הון אנושי סול ג'יי בארר Sol J. Barer

Three Board Members to Leave Distraught Drugmaker Teva

26.04.18|Lilach Baumer and Dror Reich
Teva, one of the world's largest generic drugmakers, has faced increasing difficulties the past two years
מנכ"ל ג'נרל אלקטריק ג'ון פלאנרו

General Electric, Roche Weigh Israel, Finland as Possible Locations for Joint Research Operation

22.04.18|Yoav Stoler
The World Economic Forum’s global competitiveness report for 2017-2018 ranked Israel third in innovation and Finland fourth
קנאביס קנביס רפואי מריחואנה יצוא

Israeli Cannabis Company Signs Deal With Unnamed Canadian Company Worth “Hundreds of Millions of Shekels”

16.04.18|CTech
Together Pharma announced the deal days before Israel’s cannabis export reform was blocked yet again by a ministerial dispute
אינטק פארמה ממנה את ד"ר ג'ון קוזריץ' לתפקיד יו"ר החברה

Intec Pharma Announces Public Offering of Ordinary Shares on Nasdaq

11.04.18|Dror Reich
The pharmaceutical company is currently listed on Nasdaq and the Tel Aviv Stock Exchange. Investment firm Oppenheimer & Co.will serve as the sole book-running manager
מפעל טבע נתניה

Teva and Rimsa Settle Contested $2.3-Billion Acquisition Deal Out of Court

10.04.18|Dror Reich
Teva acquired the Mexican plant in 2016 but shut it down immediately, citing discrepancies between Rimsa's regulatory filing and the actual assets, and filed a suit against the former owners
הפגנה מפגינים פיטורים טבע אשדוד

With No Buyers, Teva to Close Israeli Medical Equipment Plant

09.04.18|Dror Reich
The facility in Ashdod is one of five Teva intends to sell or close in its home country
יו"ר ועד עובדי טבע כפר סבא אלירן קוזליק

In Protest of New Bonus Plan, Teva Sued by Israeli Employees

15.03.18|Dror Reich
After announcing the cancellation of its annual bonuses for 2017 due to debt, the Israel-based drugmaker rolled out a performance-based bonus scheme for 2018 in February
מנכ"ל טבע החדש קור שולץ 2

Teva Increases Junk Senior Note Offering to $4.5 Billion

08.03.18|Lilach Baumer
Last week the debt-laden drugmaker announced a $3.5 billion-equivalent offering to repay its short-term $1.5 billion outstanding debt due July
תרופות טבע גלולות תרופה

Teva to Repay Due Loans with Junk Bond Private Offering

01.03.18|Lilach Baumer
The debt-laden generic drugmaker is offering around $3.5 billion in senior notes in both dollar and euro denominations
מנכ"ל טבע החדש קור שולץ 2

Teva Shut Down New York, Washington Offices, Says CEO

23.02.18|Dror Reich
In a meeting with investors in Israel, CEO Kåre Schultz said the Washington offices were used mainly by lobbyists, for which Teva has no further need
אורי טל טנא פרשן שוק ההון

Teva No Longer Provides Timeline for Recovery

21.02.18|Uri Tal-Tenne
In 2017, the company said it expected moderate growth in operating profits in the U.S. in 2020
מנכ"ל טבע החדש קור שולץ

Teva Turns to Meritocracy as Part of Turnaround Plan

18.02.18|Dror Reich
A new policy the company is rolling out would see Teva employees compensated according to key performance indicators
וורן באפט 2017 ברקשייר האתוויי

Berkshire Hathaway Takes Position in Generic Drugmaker Teva

15.02.18|Lilach Baumer
The holding company disclosed a $358 million stake in the struggling company
מטה טבע פתח תקווה

Teva Gets Fresh Cash, Fresh Woes

04.02.18|Dror Reich
After the troubled drugmaker finalized two deals that will enable it to repay some of its debt, S&P placed it on CreditWatch negative on Friday
מנכ"ל טבע החדש קור שולץ 2

As Part of Cost-Cutting Plan, Teva Will Shut Down Twenty or More Manufacturing Sites

10.01.18|Lilach Baumer
The drugmaker will shut down 20-25 manufacturing sites in the next two years, CEO Kåre Schultz said Monday
מנכ"ל טבע החדש קור שולץ 2

As U.S. Domestic Issuer, Teva Reveals Top Stock Owners

03.01.18|Dror Reich
Kåre Schultz, the newly-appointed CEO of generic drugmaker Teva Pharmaceutical Industries Ltd., is one of Teva's largest shareholders, a Wednesday filing to the U.S. Securities and Exchange Commission revealed
Previous ArticlesMore Articles